

**Trellus Health plc**  
("Trellus Health", the "Company" or the "Group")

**AGM Statement**

**LONDON, U.K. AND NEW YORK, U.S. (30 June 2025)** Trellus Health® plc (AIM: TRLS), a healthcare company delivering Trellus Elevate®, a digital platform that integrates data analytics with personalised, scientifically proven resilience programs and value-based solutions to manage complex chronic conditions, announces it will hold its Annual General Meeting at 1.00pm (BST) today at the Company's registered office, 201 Temple Chambers, 3-7 Temple Avenue, London, United Kingdom, EC4Y 0DT.

**Kevin L. Murphy Jr., Chairman will address the meeting with the following update:**

*"We continue to focus on Trellus Health's key commercial verticals: pharmaceutical patient support programs, clinical trial patient recruitment and retention services, and the U.S. health plan sector. Notably, Trellus Health has recently been granted preferred vendor status by a leading global contract research organisation (CRO), and whilst not revenue generating in itself, this reinforces the value of our proprietary resilience methodology.*

*"Our collaborative relationship with Johnson & Johnson remains strong and we are already delivering on key early metrics of patient satisfaction ratings and engagement.*

*"We have continued to maintain strong discipline in our cash management and have further reduced our cost base from the average monthly burn of 500k, year to date, as announced at our annual results. With effect from August 1 2025, our average monthly cash burn will be reduced to 440k per month. This has been a focus of the Group, even as we expand our go-to-market strategy within the pharmaceutical sector. These additional reductions have extended the cash runway into mid-November 2025. The Company continues to evaluate all commercial options, including ongoing discussions with a number of potential commercial partners and discussions with professional advisers in relation to fund raising options."*

**Enquiries:**

**Trellus Health plc**

<https://trellushealth.com/>

Dr. Marla Dubinsky, Chief Executive Officer and Co-Founder  
Joy Bessenger, Chief Financial Officer

**Via Walbrook PR**

**Singer Capital Markets**

Jen Boorer / James Todd / Jalin Kalaravy

Tel: +44 (0)20 7496 3000

**Walbrook PR**

Paul McManus / Lianne Applegarth /  
Alice Woodings

Tel: +44 (0)20 7933 8780 or [trellus@walbrookpr.com](mailto:trellus@walbrookpr.com)

Mob: +44 (0)7980 541 893 / +44 (0)7584 391 303/  
+44 (0)7407 804 654

**About Trellus Health plc ([www.trellushealth.com](http://www.trellushealth.com))**

Trellus Health® (AIM: TRLS) is a healthcare company providing value-based innovative solutions and services, helping people with chronic conditions take control of their health through a proven, scientifically validated self-management solution and continuous, personalised support. Trellus Health's approach empowers patients to better navigate the emotional and physical challenges of their conditions, leading to significant cost savings, enhanced treatment adherence, and long-term, sustainable health outcomes.

Trellus Health integrates its proprietary resilience-based methodology with the technology, tools, and expert coaching and educator team to deliver Trellus Elevate®, a whole-person technology-enhanced condition management platform. The Company is initially focusing on chronic costly GI conditions that have a high mental health burden, such as Inflammatory Bowel Disease (IBD). Among IBD patients, applying Trellus Elevate resulted in over 90% fewer hospitalisations and a reduction of over 70% in emergency room visits. Given the common emotional and mental health struggles associated with a variety of chronic conditions, Trellus Health considers its approach to have potential utility and demand across many conditions.

Trellus Health also offers a seamless solution for pharmaceutical partners from clinical trials to commercialisation, harnessing resilience-based methods to drive both trial and patient support success by empowering patients to stay

engaged, adhere to their treatment, and manage their health confidently.

The Company was founded by Mount Sinai faculty members Marla C. Dubinsky, MD and Laurie Keefer, PhD, both world-leading experts at treating and healing both the physical and emotional impacts of IBD and have been innovators for whole-person healthcare for a combined 50 years.

Shares in Trellus Health were admitted to trading on AIM in May 2021, under the ticker TRLS. For more information, visit: [www.trellushealth.com](http://www.trellushealth.com)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@lseg.com](mailto:ms@lseg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

AGMUKUSRVSNUAR